Opportunity Information: Apply for PAR 25 319
The NIH is offering this grant opportunity to push forward HIV/AIDS research that fits squarely within the mission of the National Institute on Deafness and Other Communications Disorders (NIDCD). The program is titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" and is listed as PAR-25-319. It uses the R01 mechanism, meaning it is meant for substantial, hypothesis-driven projects that can make a clear scientific contribution, and it sits in the health funding area (CFDA 93.173). The main idea is to encourage researchers to tackle HIV/AIDS questions that directly connect to communication disorders and sensory systems, rather than broader HIV topics that fall outside NIDCD's scope.
A key requirement is that proposed work should align with the NIH Office of AIDS Research (OAR) HIV research priorities, which serve as the federal roadmap for what HIV research areas are most urgent and high-impact. In practice, applicants are expected to frame their aims in a way that clearly maps onto those OAR priorities while staying focused on NIDCD-relevant domains. The FOA highlights specific scientific areas of interest: hearing, balance, taste, smell, voice, speech, and language. This creates a clear lane for studies on how HIV infection, HIV-related inflammation, co-infections, comorbidities, or HIV treatments might influence auditory and vestibular function, chemosensory function, or speech and language processes, as well as how these conditions can be assessed, prevented, or treated in people affected by HIV.
The "Clinical Trial Optional" label means you may submit either a non-trial research application or one that includes a clinical trial component. However, if you do propose a clinical trial, this FOA limits support to low-risk clinical trials only. That typically implies interventions with minimal potential for harm, strong safety profiles, and careful monitoring plans, such as behavioral interventions, low-risk diagnostic or screening strategies, or other clinical research designs that do not involve major invasive procedures or high-risk investigational products. Applicants considering trials should be prepared to justify why the study is low risk and to present appropriate human subjects protections, oversight, and feasibility plans consistent with NIH expectations for clinical research.
Eligibility is broad and is not restricted to universities alone. In addition to standard applicants like state and local governments, public and private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), and for-profit organizations (including small businesses), the announcement explicitly notes a wide range of other eligible applicant types. These include historically underserved and mission-driven institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). It also includes eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and Indian/Native American tribal governments that are not federally recognized. Importantly, the FOA also allows non-U.S. entities (foreign organizations) to apply, which can be especially relevant for HIV research conducted in international settings or in collaboration with global partners.
From an administrative standpoint, this is a discretionary grant program run by the National Institutes of Health. The original closing date listed is January 7, 2028, indicating a multi-year window in which applications can be submitted across the standard NIH submission cycles that fall before that end date. The listing does not specify an award ceiling or the expected number of awards in the provided source data, so applicants typically need to rely on NIH institute guidance, paylines, and the usual R01 budget justification practices to shape a realistic request.
Overall, this FOA is best understood as a targeted invitation: bring strong HIV/AIDS science that speaks to OAR priorities, but do it through the lens of hearing, balance, taste, smell, voice, speech, or language. The most competitive applications will usually be the ones that make a tight case for why the proposed HIV/AIDS question is high priority, why NIDCD is the right scientific home for the work, and how the study design (whether basic, translational, clinical, or low-risk trial) will produce results that can meaningfully improve understanding, prevention strategies, diagnostics, or interventions affecting communication and sensory health in people impacted by HIV.Apply for PAR 25 319
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173.
- This funding opportunity was created on 2025-01-08.
- Applicants must submit their applications by 2028-01-07.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional) - PAR-25-319
What is this funding opportunity?
This is an NIH discretionary grant funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)." The funding announcement is PAR-25-319, and it supports HIV/AIDS research that fits squarely within the mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD).
Which NIH institute is this opportunity aligned with?
The opportunity is intended for HIV/AIDS research that is relevant to NIDCD mission areas, including communication disorders and sensory systems (for example, hearing and balance, taste and smell, and speech/language-related domains).
What grant mechanism does this program use?
This opportunity uses the NIH R01 mechanism. R01s are designed for substantial, hypothesis-driven projects that aim to make a clear scientific contribution.
What is the CFDA number or health funding area listed for this opportunity?
The opportunity is listed in the health funding area under CFDA 93.173.
What kinds of HIV/AIDS research does this FOA want to fund?
The FOA encourages HIV/AIDS research that directly connects to NIDCD-relevant domains rather than broader HIV topics outside NIDCD scope. The announcement highlights scientific areas of interest such as hearing, balance, taste, smell, voice, speech, and language.
What specific scientific areas are emphasized?
The FOA explicitly highlights hearing, balance, taste, smell, voice, speech, and language as priority domains for HIV/AIDS research under this program.
How should applicants align their research aims with federal HIV priorities?
Proposed work is expected to align with the NIH Office of AIDS Research (OAR) HIV research priorities, which serve as a federal roadmap for urgent and high-impact HIV research. Applicants are expected to frame their aims so they clearly map onto OAR priorities while staying focused on NIDCD mission areas.
What HIV-related factors can be studied under this FOA (as described in the announcement)?
The FOA notes that studies may address how HIV infection, HIV-related inflammation, co-infections, comorbidities, or HIV treatments might influence auditory and vestibular function, chemosensory function, or speech and language processes.
Does this FOA allow clinical trials?
Yes. The FOA is labeled "Clinical Trial Optional," meaning applications may be submitted either without a clinical trial or with a clinical trial component.
If proposing a clinical trial, are there restrictions on what can be supported?
Yes. If a clinical trial is proposed under this FOA, support is limited to low-risk clinical trials only.
What does "low-risk clinical trial" mean in the context of this announcement?
In this FOA, "low risk" is described as typically involving interventions with minimal potential for harm and strong safety profiles, along with careful monitoring plans. Examples mentioned include behavioral interventions and low-risk diagnostic or screening strategies, as well as other clinical research designs that do not involve major invasive procedures or high-risk investigational products.
What should applicants include if they propose a low-risk clinical trial?
Applicants should be prepared to justify why the study is low risk and to provide appropriate human subjects protections, oversight, and feasibility plans consistent with NIH expectations for clinical research.
Who is eligible to apply?
Eligibility is broad and not restricted to universities. Eligible applicants include state and local governments, public and private institutions of higher education, nonprofits (501(c)(3) and non-501(c)(3)), and for-profit organizations (including small businesses).
Are mission-driven and historically underserved institutions explicitly eligible?
Yes. The FOA explicitly notes eligibility for institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are community-based or faith-based organizations eligible to apply?
Yes. The announcement explicitly includes faith-based or community-based organizations among eligible applicant types.
Are federal agencies eligible applicants?
Yes. The FOA includes eligible federal agencies among the entities that may apply.
Are U.S. territories or possessions included as eligible applicants?
Yes. The FOA includes U.S. territories or possessions as eligible applicant types.
Are tribal governments eligible to apply?
Yes. The FOA includes Indian/Native American tribal governments that are not federally recognized among eligible applicants.
Can non-U.S. (foreign) organizations apply?
Yes. The FOA allows non-U.S. entities (foreign organizations) to apply, which may be relevant for international HIV research settings or global collaborations.
What is the overall purpose or "fit" that reviewers are likely to look for?
This FOA is a targeted invitation to bring strong HIV/AIDS science that aligns with OAR priorities and is clearly rooted in NIDCD domains such as hearing, balance, taste, smell, voice, speech, or language. Applications are expected to make a tight case for why the research question is high priority, why NIDCD is the right scientific home, and how the study design will produce results that improve understanding, prevention strategies, diagnostics, or interventions affecting communication and sensory health in people impacted by HIV.
What is the application deadline window provided in the announcement?
The original closing date listed is January 7, 2028, indicating a multi-year window in which applications can be submitted across standard NIH submission cycles that occur before that end date.
Does the provided information include an award ceiling or expected number of awards?
No. The provided source information does not specify an award ceiling or the expected number of awards.
How should applicants think about budget levels given the lack of a stated ceiling?
Because the provided information does not list an award ceiling, applicants typically rely on NIH institute guidance, paylines, and standard R01 budget justification practices to shape a realistic budget request.
Is this opportunity intended only for basic science?
No. The FOA is described as supporting strong HIV/AIDS science through NIDCD-relevant lenses and notes that studies may be basic, translational, clinical, or include a low-risk clinical trial component.
What types of outcomes or impacts are emphasized?
The FOA emphasizes producing results that can meaningfully improve understanding, prevention strategies, diagnostics, or interventions affecting communication and sensory health in people impacted by HIV.
Browse more opportunities from the same category: Health
Next opportunity: Management, Species, Nuisance Wildlife Management (RAM Number: FXSBA53256122) and Management, Species, Black and Brown Bear Study, (RAM Number: FXSBA53256120), Joint Base Elmendorf-Richardson (JBER), Alaska
Previous opportunity: Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 319
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 319) also looked into and applied for these:
| Funding Opportunity |
|---|
| Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) Apply for PA 25 169 Funding Number: PA 25 169 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) Apply for PA 25 150 Funding Number: PA 25 150 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) Apply for PAR 25 048 Funding Number: PAR 25 048 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) Apply for PAR 25 318 Funding Number: PAR 25 318 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) Apply for PAR 25 358 Funding Number: PAR 25 358 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) Apply for PAR 25 250 Funding Number: PAR 25 250 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Disseminating PCOR Evidence for Long COVID Care into Practice Through Up-to-Date Clinical Decision Support Apply for RFA HS 25 001 Funding Number: RFA HS 25 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Single Source: Bench to Bassinet Congenital Heart disease Advancing New understanding in GEnomics Cohort (B2B CHANGE Cohort) Data Coordinating Center (U01 Clinical Trial Not Allowed) Apply for RFA HL 26 007 Funding Number: RFA HL 26 007 Agency: National Institutes of Health Category: Health Funding Amount: $4,010,000 |
| Rural Communities Opioid Response Program – Northern Border Rural Workforce Apply for HRSA 25 011 Funding Number: HRSA 25 011 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed) Apply for RFA AI 25 006 Funding Number: RFA AI 25 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Communities Opioid Response Program – Pathways Apply for HRSA 25 093 Funding Number: HRSA 25 093 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional) Apply for PAR 25 352 Funding Number: PAR 25 352 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Apply for PAR 25 353 Funding Number: PAR 25 353 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| T32 Training Program to Promote Broad Participation (T32 Clinical Trial Not Allowed) Apply for PAR 25 356 Funding Number: PAR 25 356 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional) Apply for RFA AI 24 079 Funding Number: RFA AI 24 079 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Harmonization of systems and services to embed HIV service delivery into primary health care (HARMONIZE) Apply for 7200AA25RFA00003 Funding Number: 7200AA25RFA00003 Agency: Agency for International Development Category: Health Funding Amount: $780,000,000 |
| Rural Program of All-Inclusive Care for the Elderly (PACE) Planning and Development Apply for HRSA 25 101 Funding Number: HRSA 25 101 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Poison Control Program Competitive Supplement Apply for HRSA 25 097 Funding Number: HRSA 25 097 Agency: Health Resources and Services Administration Category: Health Funding Amount: $265,188 |
| NIA Postdoctoral Fellowship Award to Promote Broad Participation in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed) Apply for PAR 24 332 Funding Number: PAR 24 332 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Predoctoral Fellowship Award to Promote Broad Participation in Translational Research for AD/ADRD (F31 Clinical Trial Not Allowed) Apply for PAR 24 333 Funding Number: PAR 24 333 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 319", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.